- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940361
Ultrashort Echo Time (UTE) MRI for Applicator Reconstruction in Gynaecologic Cancer Brachytherapy (UTE)
The goal of this clinical study is to learn whether an ultrashort echo time (UTE) MRI scan can show the position of brachytherapy applicators and needles more accurately than standard MRI scans in adults with gynaecologic cancer (cervical, endometrial, or vaginal cancer) who are receiving MRI-guided internal radiotherapy (brachytherapy).
The main questions it aims to answer are:
- Does UTE MRI locate the applicator and needle tips more accurately than standard T2-weighted (T2W) and proton-density-weighted (PDW) MRI, when compared with CT?
- Does UTE MRI show a clearer contrast between the applicator and the surrounding tissue?
Researchers will compare applicator positions reconstructed from UTE, T2W, and PDW MRI with CT taken on the same day as the reference standard. They will also check whether differences in applicator reconstruction change the planned radiation dose, and whether image features (radiomics) from UTE MRI before treatment and before brachytherapy help predict cancer recurrence.
Participants will:
- Receive their usual standard brachytherapy treatment, which is not changed by this study
- Have one additional MRI sequence (UTE, about 8 minutes) added to their standard MRI and CT scans at each brachytherapy planning session, with the applicator in place
- Have an additional UTE sequence added to their routine MRI before treatment and before brachytherapy
- Be followed during routine clinical visits for disease outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background MRI-guided adaptive brachytherapy is the standard of care for locally advanced gynaecologic cancer. T2-weighted MRI is the reference sequence for target delineation, but applicator and interstitial needle reconstruction on T2W MRI is limited by low contrast between the uterus and titanium applicators and by susceptibility artefacts, with reported geometric distortion of up to about 7 mm. Proton-density-weighted MRI (TE about 5.5 ms) improves tandem visualisation but remains limited for interstitial needles and residual blooming artefact. Ultrashort echo time (UTE) MRI (TE below 1 ms) captures signal from very short-T2 structures and is expected to reduce susceptibility artefact around metallic and plastic applicators. No prospective study has compared UTE with PDW and T2W MRI for intracavitary/interstitial applicator reconstruction in gynaecologic brachytherapy.
Hypothesis UTE MRI will localise the applicator tip more accurately than PDW and T2W MRI, with a mean tip-localisation error of no more than 1.2 mm relative to same-day CT, and will provide a higher uterus-to-applicator contrast-to-noise ratio (CNR), with about 8 minutes of additional scan time.
Study design Single-centre, prospective, single-group study at the Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital, Mahidol University. Standard treatment is not altered.
Phase 1 - Phantom validation An MR- and CT-compatible phantom holding tandem-ring, tandem-ovoid, vaginal cylinder, intracavitary/interstitial applicators and interstitial needles in multiple orientations will be imaged with CT and MRI (T1W, T2W, UTE) without moving the applicator. Image quality (SNR, CNR, apparent applicator diameter, tip/channel visibility, geometric distortion, susceptibility artefact) will be assessed. Source dwell positions will be verified by autoradiography using an Ir-192 source. Dosimetric impact will be assessed with AAPM TG-43 calculations on simulated targets and organs at risk.
Phase 2 - Clinical validation After applicator insertion, at each brachytherapy planning session participants will undergo standard CT and MRI (T2W, PDW) with an additional 3D UTE sequence (1.5 mm isotropic, TE below 0.1 ms) on a Philips 1.5T Ingenia Ambition X system, with the applicator in situ and minimal time between scans. Three experienced medical physicists will independently reconstruct applicators on each image set, blinded and in randomised order. Applicator-based rigid registration between CT and MRI with a registration quality score will be used to separate reconstruction error from applicator displacement; only registrations meeting predefined acceptance criteria will be analysed. Comparison plans (CT reference, T2W, UTE) will use identical contours, dwell positions, and dwell times so that dose differences reflect reconstruction alone.
Phase 3 - Radiomics An additional UTE sequence will be acquired with routine T2W and DWI at pre-treatment and pre-brachytherapy time points. Radiomic features will be extracted from tumour ROIs (MIM software) and evaluated for prognostic value for locoregional and distant recurrence, in addition to existing T2W- and DWI-based models, using Kaplan-Meier and Cox proportional hazards analyses.
Sample size and analysis Target enrolment is 50 adult patients (about 150 imaging sessions). Assuming tip error of 1.2 +/- 1.0 mm for UTE versus 1.8 +/- 1.2 mm for PDW, a paired t-test with two-sided alpha 0.05 and 80% power (d = 0.46) was used. Agreement with CT will be assessed by Bland-Altman analysis; sequences will be compared with repeated-measures ANOVA or linear mixed-effects models; inter- and intra-observer agreement by ICC; and dosimetric parameters (CTV-HR D90/D98, OAR D2cc and others) with correction for multiple comparisons.
Support Philips (Thailand) Ltd. provides research equipment support without funding. The company has no role in study design, participant selection, data collection, analysis, interpretation, writing, or the decision to publish.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tissana Prasartseree, M.D.
- Phone Number: 66625246101
- Email: tissana.p@gmail.com
Study Contact Backup
- Name: Pittaya Dankulchai, M.D.
- Phone Number: 66966233606
- Email: pittaya.dan@mahidol.ac.th
Study Locations
-
-
Bangkok
-
Bangkok, Bangkok, Thailand, 10700
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
Contact:
- Tissana Prasartseree, M.D.
- Phone Number: 66625246101
- Email: tissana.p@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator
- Locally advanced cervical, endometrial, or vaginal cancer undergoing MRI-guided BT
- Age ≥ 18 years
- ECOG 0-2
- Written informed consent
Exclusion Criteria:
- MRI contraindication (incompatible implant, severe claustrophobia)
- non-MRI-compatible applicator required
- inability to tolerate ~8 mins additional scan time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: UTE MRI
Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator. At every planning/fraction session: T2W, PDW, 3D UTE (1.5 mm isotropic) and same day CT (reference), all with applicator in situ on a Philips 1.5T system. An additional UTE sequence will be acquired alongside the standard T2W and DWI sequences at pre-treatment and pre-brachytherapy time points. |
Ultrashort Echo Time sequence (EFO 033), TE < 0.1 ms, investigational Philips sequence, on Philips 1.5T MR Systems Ingenia Ambition X release 5.7. 3D UTE (1.5 mm isotropic) acquired at every planning/fraction session with applicator in situ, in addition to T2W and PDW (~8 mins additional scan time).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Applicator/needle tip-localisation error
Time Frame: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Applicator/needle tip-localisation error of UTE among the T2W, PDW MRI sequences, using same day CT as reference (geometric gold standard). Reported in millimetres. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
|
Contrast-to-noise ratio (CNR)
Time Frame: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Contrast-to-noise ratio (CNR) between uterus and applicator of UTE among the T2W and PDW MRI sequences. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage dose difference of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT
Time Frame: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Dosimetric agreement of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT, including CTV-HR D90, CTV-HR D98, CTV-HR V100, CTV-IR D90, CTV-IR D98, and Bladder, Rectum, Sigmoid Colon and Small Bowel D0.1cc, D1cc and D2cc. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
|
Radiomics prognostic value for locoregional and distant recurrence
Time Frame: Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
|
Radiomics with UTE at pre-treatment and pre-brachytherapy timepoints for locoregional and distant recurrent prognostic value in addition to the existing T2W- and DWI-based model (Kaplan-Meier survival analysis and Cox regression analysis). Reported as Hazard Ratio (HR) with 95% CI. |
Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Neoplasms
- Vaginal Diseases
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
- Vaginal Neoplasms
- Diagnostic Techniques and Procedures
- Diagnosis
- Tomography
- Diagnostic Imaging
- Magnetic Resonance Imaging
Other Study ID Numbers
- Si 784/2569(IRB1)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.